|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Quanterix partners BIDMC to develop TB test
|
|
Quanterix
: 14 February, 2012 (New Product) |
|
|
Quanterix is planning to apply its cutting-edge technology towards the development of an improved test to aid in the diagnosis of active tuberculosis (TB). |
|
In collaboration with the Forsyth Institute and Beth Israel Deaconess Medical Center (BIDMC), Quanterix will validate novel low abundance protein biomarkers that may be useful for identifying individuals with active disease. Through this strategic partnership, Quanterix will continue to expand its infectious disease applications to include the development of a fast and simple test that will provide accurate diagnosis of active TB in high-burden countries.
"The Forsyth Institute has utilised a proteomics-based approach to identify a panel of novel M tuberculosis markers present in the urine of human patients with active TB, but conventional protein detection platforms lack the analytical sensitivity to reliably detect these proteins in urine or blood. Using SiMoA, we are routinely able to improve the sensitivity of existing immunoassays by more than 1,000-fold, enabling accurate measurement of analytes that have previously been considered undetectable. Applying our technology to evaluate biomarkers that could not otherwise be detected will allow us to address a variety of important unmet medical needs, including the development of an improved test for the diagnosis of active tuberculosis," said David Duffy, PhD, Vice President of Research at Quanterix.
Dr Antonio Campos-Neto, Director of Forsyth's Global Infectious Disease Research Center, added: "Diagnosis of tuberculosis in most of the world remains antiquated and inaccurate. The development of a more sensitive and specific TB test could save hundreds of thousands of lives annually. We are thrilled to partner with Quanterix to combine our proprietary content with their SiMoA technology."
"Identifying individuals with active tuberculosis and distinguishing them from those with latent infection is critical to minimise the spread of disease and to provide prompt and appropriate therapy. I look forward to working with the Forsyth Institute and Quanterix to validate these biomarkers and ultimately to develop and validate a superior point-of-care test," commented Nira Pollock, MD, PhD, Clinical Collaborator and Assistant Professor of Medicine, Harvard Medical School/Division of Infectious Diseases, BIDMC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
